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Testicular germ cell tumour (TGCT) is the most common malignancy in young males. Although most TGCTs are sensitive to
cisplatin-based chemotherapy, significant numbers of TGCT patients still relapse and die each year because of the development of
resistance to cisplatin. Previously, we first reported that a key regulator of the mitotic checkpoint, mitotic arrest deficient-2 (MAD2),
was a mediator of cisplatin sensitivity in human cancer cells. In this study, we investigated whether MAD2 played a role in cellular
sensitivity to cisplatin in TGCT cells and the underlying molecular mechanisms responsible. Using 10 TGCT cell lines, we found that
increased MAD2 expression was correlated with cellular sensitivity to cisplatin, which was associated with activation of the MEK
pathway. Treatment of cells expressing high levels of MAD2 with an MEK inhibitor, U0126, led to cellular protection against cisplatin-
induced apoptosis. Inactivation of MAD2 by transfecting a dominant-negative construct in TGCT cells with high levels of MAD2
resulted in the suppression of MEK pathway and resistance to cisplatin-induced cell death. These results support previous suggestion
on the involvement of mitotic checkpoint in DNA damage response in human cancer cells and demonstrate a possible molecular
mechanism responsible for the MAD2-mediated sensitivity to cisplatin in TGCT cells. Our results also suggest that downregulation of
MAD2 may be an indicator for identification of TGCT cancer cells that are potentially resistant to cisplatin-based therapy.
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Testicular germ cell tumour (TGCT) is the most common type of
malignancy in young males aged 15–35 years and the incidence is
increasing steadily throughout the world (McGlynn et al, 2003). In
the past 30 years, the incidence of TGCT has doubled, especially in
young men with a mean age of 36 years at diagnosis (Power et al,
2001). Since the introduction of cisplatin-based chemotherapy in
the mid-1970s, the mortality of this disease has been reduced
significantly and the 5-year survival rate can be achieved in over
85% of patients when detected early (Jones and Vasey, 2003).
Hence, cisplatin is considered as the most efficient single agent in
the treatment of TGCT. However, owing to the development of
cisplatin resistance, a number of young patients die every year.
Multiple mechanisms have been suggested in the development
of cisplatin resistance including reduction of intracellular drug
accumulation, overexpression of thiol-containing molecules, in-
creased DNA damage repair, upregulation of antiapoptotic genes
as well as defects in certain signal-transduction pathways (Siddik,
2003). Recently, mitogen-activated protein kinase (MAPK) (Lavoie
et al, 1996) signalling pathway has been suggested to play a role in
cisplatin-mediated cytotoxicity in carcinoma cells (Siddik, 2003).
There are three major MAPK subfamilies: extracellular signal-
regulated kinases (ERK), c-jun N-terminal kinases and p38
kinases. These MAPK members participate in integrating extra-
cellular signals to regulate cell proliferation, differentiation, cell
survival and apoptosis (Dent and Grant, 2001). Wang et al (2000)
have shown that all three kinase members are activated after
exposure to cisplatin in cervical cancer cells. They, however,
suggest that only ERK activation is the most important factor for
cisplatin-induced apoptosis, which is consistent with the demon-
stration that the cisplatin-induced ERK activation contributes to
regulation of p53 by phosphorylating the tumour suppressor at
serine-15 (Persons et al, 2000). Moreover, Yeh et al (2002) have
also reported that inhibition of the MEK–ERK pathway leads to
cisplatin resistance in cervical carcinoma cells. Contradictory
results have also been reported that activation of ERK pathway by
cisplatin antagonises apoptosis in ovarian carcinoma cell lines
(Persons et al, 1999). In addition, inhibition of cisplatin-induced
ERK activation enhances sensitivity to cisplatin in both cisplatin-
sensitive and cisplatin-resistance ovarian cells carcinoma cell lines
(Cui et al, 2000). These studies indicate the importance of the
MEK/ERK pathway in cisplatin-induced apoptosis. Recently, a
study has shown that MEK/ERK activation is also important in
cisplatin-induced apoptosis in human TGCT cell lines. The authors
have shown that after cisplatin treatment, MEK and ERK are dually
phosphorylated which is associated with caspase 3 activation.
Treatment with MEK inhibitors not only downregulates the level of
ERK phosphorylation but also reduces the apoptotic rate of
cisplatin-treated TGCT cell lines (Schweyer et al, 2004a). These
results suggest that activation of MEK/ERK pathway may play an
important role in cisplatin-induced cell death in TGCT cells.
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sRecently, we have demonstrated that mitotic arrest deficient-2
(MAD2) plays a key role in cisplatin sensitivity in nasopharyngeal
carcinoma (NPC) cells (Cheung et al, 2005). Mitotic arrest
deficient-2 is one of the key regulators of the mitotic checkpoint,
which plays an essential role in the proper segregation of
chromosomes in each cell division (Rudner and Murray, 1996).
Recently, the MAD2-mediated mitotic checkpoint has been shown
to be involved in cellular response to DNA damage in both human
and yeast cells (Garber and Rine, 2002; Mikhailov et al, 2002).
Previously, we have found that ectopic MAD2 expression in NPC
cells leads to increased sensitivity to cisplatin via activation of the
apoptosis pathway (Cheung et al, 2005). In addition, we have
shown that the MAD2-mediated chemosensitivity to vincristine, a
microtubule-disrupting agent, is associated with activation of the
MEK pathway (Wang et al, 2003). These results suggest that MAPK
pathways may be important in MAD2-mediated sensitivity to
certain anticancer drugs.
The aim of this study was to investigate whether MAD2 played a
role in cisplatin-induced apoptosis in TGCT cells and whether
MEK/ERK pathway was involved in this process. Using 10 TGCT
cell lines, we found that increased MAD2 expression was correlated
with sensitivity to cisplatin and activation of the MEK/ERK
pathway. Suppression of MEK/ERK pathway in cells with high
levels of MAD2 conferred resistance to cisplatin. Inactivation of
MAD2, on the other hand, led to suppression of the MEK/ERK
pathway and decreased sensitivity to cisplatin-induced apoptosis.
Our results suggest that the MAD2-mediated sensitivity to cisplatin
may be regulated through modification of the MEK pathway.
MATERIALS AND METHODS
Cell lines and cell culture conditions
Ten TGCT cell lines were used in this study. Six TGCT cell lines
were (GH, 833K, SuSa, SuSa-CP, GCT27 and GCT27R) kindly
provided by Professor J Masters (University College, London, UK)
and a human cervical carcinoma cell line, HeLa, obtained from
American Type Culture Collection (Rockville, MD, USA) was used
as a positive control. They were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal
bovine serum (FBS) and penicillin/streptomycin. Three TGCT cell
lines (1411HP, NT2/D1, 2102EP) obtained from Professor P
Andrews (University of Sheffield, UK) were grown in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS and
penicillin/streptomycin, and NCCIT cell line (kindly provided by
Professor C Bokemeyer; University of Tuebingen, Germany) was
cultured in RPMI 1640 supplemented with 10% FCS and penicillin/
streptomycin. All cell lines were cultured at 371C in a humidified
atmosphere with 5% CO2. The characteristics and the origin of all
the TGCT cell lines used in this study are listed in Table 1. The
MEK1/2 inhibitor, U0126, was purchased from Cell Signaling
Technology (Beverly, MA, USA).
Colony-forming assay
One thousand to 3000 cells were plated in 12-well plates according
to the individual plating efficiencies. Cisplatin (David Bull
Laboratories, Victoria, Australia) or Taxol (Calbiochem, San
Diego, CA, USA) was added 24h after plating. After 10–14 days
of incubation, the cells were fixed in 70% ethanol and stained in
10% Giemsa. Colonies consisting of 50 or more cells were counted
and survival curves were plotted. Two wells were used for each
concentration and the corresponding controls. Each experiment
was repeated at least three times and each data point represented
the mean and standard derivation.
Western blotting
Cell lysates were prepared by suspending cell pellets in lysis buffer
(50mmoll
 1 Tris-HCl (pH 8.0), 150mmoll
 1 NaCl, 1% NP40,
0.5% sodium deoxycholate and 0.1% SDS) containing proteinase
inhibitors (1mgml
 1 aprotinin, 1mgml
 1 leupeptin and 1mmoll
 1
phenylmethylsulphonyl fluoride). Protein concentration was mea-
sured using DC Protein Assay kit (Bio-Rad, Hercules, CA, USA).
Same amount of protein (30mg) was loaded onto a SDS–
polyacrylamide gel for electrophoresis and then blotted onto a
nitrocellulose membrane (Amersham, Piscataway, NJ, USA). After
blocking with 10% nonfat milk or 5% bovine serum albumin in
TBS-T for 1h, the membrane was incubated with primary
antibodies for 1h at room temperature against MAD2 (BD
Transduction Laboratories, Franklin Lakes, NJ, USA), p-MEK, p-
p44/42 MAP kinase, p-Elk-1, PARP (Cell Signaling Technology,
Beverly, MA, USA), HA (Roche Diagnostics, Indianapolis, IN,
USA) or actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Then, the membrane was incubated with suitable secondary
antibodies against rabbit immunoglobulin G, mouse immuno-
globulin G or goat immunoglobulin G (Amersham, Piscataway, NJ,
USA). Signals were visualised by enhanced chemiluminescence
Western blotting system (Amersham, Piscataway, NJ, USA).
Expression of actin was also used as an internal loading control.
Immunocytochemistry
Five thousand cells were plated on chamber slides of 28mm
2
overnight. The cells were fixed in 4% paraformaldehyde in PBS for
25min. The cells were immersed in 0.6% H2O2 for 30min.
Immunocytochemistry was then performed with the use of
Vectastain
s Elite ABC Kit (ABC kit) according to the manufac-
turer’s manual (Vector Laboratories Inc., Burlingame, CA, USA).
Briefly, nonspecific binding of the antibodies was blocked by 10%
Table 1 Characteristics of TGCT cell lines
Cell line Site of origin Histology Characteristics References
GH Primary NSGCT EC Wang et al (1997)
GCT27 Primary NSGCT EC Pera et al (1987)
GCT27R
a Primary NSGCT EC Kelland et al (1992)
NCCIT Primary mediastinal NSGCT EC, S Damjanov et al (1993)
NT2/D1 Lung metastasis NSGCT Pluripotent EC Andrews et al (1984)
SuSa Primary NSGCT EC, T Hogan et al (1977)
SuSa-CP
b Primary NSGCT EC, T Walker et al (1990)
833K Abdominal metastasis NSGCT EC, T Bronson et al (1980)
1411HP Primary NSGCT EC, Y Vogelzang et al (1985)
2102EP Primary NSGCT EC Wang et al (1980)
EC¼embryonal carcinoma; NSGCT¼non-seminomatous germ cell tumour; S¼seminoma; T¼teratoma; Y¼yolk sac tumour.
aAcquired resistance cell line derived from
GCT27.
bAcquired resistance cell line derived from SuSa.
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slides were incubated with MAD2 antibodies (BD Transduction
Laboratories, Franklin Lakes, NJ, USA) in 10% normal horse
serum at 41C overnight. They were then incubated with
biotinylated secondary antibodies provided in the ABC kit at
room temperature for an hour. They were then incubated with
ABC reagent at room temperature for 30min. Signals were
visualised with diaminobenzidine (Dako Corp., Hamburg, Ger-
many). Cells were counterstained with Mayer’s haematoxylin and
were mounted. MAD2-positive expression was stained as brown
signals in both nucleus and cytoplasm. The overall staining
intensity (both nuclear and cytoplasmic staining) was scored using
a grading scale as 0 (negative), 1 (weak), 2 (moderate) or 3
(strong).
Terminal deoxynucleotidyl transferase-mediated nick end
labelling
Five thousand cells were plated onto chamber slides of 28mm
2.
Cisplatin was added 24h after plating and incubated for 4 days.
The cells were fixed in 4% paraformaldehyde in PBS for 25min. In
situ death detection kit, Fluorescein, was used to detect apoptotic
cells according to the manufacturer’s manual (Roche Diagnostics,
Indianapolis, IN, USA). The percentage of terminal deoxynucleo-
tidyl transferase-mediated nick-end labelling (TUNEL)-positive
cells was calculated as the number of TUNEL-positive cells over
the total number of cells counted 100. At least 500 cells were
counted from three random fields under  200 magnification in
each experiment. Each experiment was repeated twice. Each data
point represented the mean and standard derivation. Po0.05 was
considered statistically significant as determined by two-tailed
Student’s t-test.
3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium
bromide assay
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
assay proliferation assay was performed according to the
manufacturer’s manual (Roche Diagnostics, Indianapolis, IN,
USA). Briefly, 3000 cells were plated in 96-well plates and cisplatin
was added 24h later for indicated time points. Following overnight
culture, 10ml of MTT labelling reagent was added and the cells
were incubated for 4h at 371C. Afterwards, 100ml of solubilising
reagent was added and the plates were incubated at 371C
overnight. Absorbance at 570nm was measured with Labsystem
multiscan microplate reader (Merck Eurolab, Dietikon Schweiz).
Each time point was carried out in triplicate and each experiment
was repeated at least twice. Each data point represented the mean
and standard deviation. Po0.05 was considered statistically
significant as determined by two-tailed Student’s t-test.
Transfection
GH cells were seeded 24h before transfection and semiconfluent
monolayer cells were transfected with a HA-tagged dominant-
negative construct of MAD2 (MAD2DC) using Fugene 6 Transfec-
tion Reagent (Roche Diagnostics, Indianapolis, IN, USA) according
to the manufacturer’s manual. For plasmid construction, a 1.5-kb
fragment containing HA-tagged truncated form of human MAD2
cDNA (MAD2DC) was cloned into pLenti6/V5-D-TOPO expression
vector by TOPO cloning reaction (Invitrogen, Carlsbad, CA, USA).
MAD2DC lacks the C-terminal 10 amino acids that is necessary for
the function of MAD2 (Canman et al, 2002). Cisplatin was added
48h post-transfection. The transfected cells were treated and
harvested at indicated time points for further analysis. For the
control experiments, cells were transfected with pLenti6/V5-D-
TOPO expression vector alone.
RESULTS
Increased MAD2 expression correlates with sensitivity to
cisplatin
To investigate whether MAD2 expression was associated with
cellular sensitivity to cisplatin, we first examined the expression of
MAD2 in 10 TGCT cell lines using HeLa cell line as a positive
control because it was shown to express a relatively high level of
MAD2 (Wang et al, 2000). As shown in Figure 1A, 40% of the
TGCT cell lines (four out of 10) expressed lower level of MAD2
compared to HeLa cells. Among the 10 TGCT cell lines tested,
MAD2 protein level was the lowest in GCT27, 2102EP and 1411HP
cell lines and it was the highest in NCCIT and GH cell lines
(Figure 1A). To confirm these results, we performed immuno-
histochemical staining of MAD2 on the cell lines, and we observed
that MAD2 expression was found in both nucleus and cytoplasm.
The overall MAD2 expression intensity in 1411HP, 2102EP and
GCT27 cell lines was weak compared to NCCIT and GH cell lines
(Figure 1B). These results supported our results generated from
Western blotting.
Colony-forming assay on the cellular sensitivity to cisplatin
showed that the three cell lines with low MAD2 protein expression
(dotted lines) were more resistant than the ones with relatively
high MAD2 expression (solid lines) (Figure 1C). For the
convenience of comparison, we calculated the inhibition concen-
trations of 50 and 90% colony-forming ability (IC50,I C 90) shown in
Table 2. IC50 and IC90 concentrations required for the cells with
low MAD2 expression were much higher than the cell lines with
high MAD2 expression (up to six-fold). These results indicated
that attenuated MAD2 expression in TGCT cells was associated
with decreased sensitivity to cisplatin (Po0.01). This association
between MAD2 and cisplatin sensitivity was consistent with our
previous studies showing that NPC cell lines with low MAD2
protein expression were more resistant to cisplatin-induced
apoptosis than cells with relatively high levels of MAD2 expression
(Cheung et al, 2005). However, a reverse correlation of MAD2
expression and sensitivity to cisplatin was found in acquired
cisplatin-resistant pairs (SuSa, SuSa-CP and GCT27, GCT27R)
(Figure 1D), suggesting differential roles of MAD2 in intrinsic and
acquired cisplatin resistance. To confirm these results, we
performed TUNEL assay to study if the differential sensitivity to
cisplatin in these cell lines was correlated to apoptosis rate. As
shown in Figure 1E, we found that in agreement with the results
generated from colony-forming assay, the cell lines expressing
relatively high levels of MAD2 showed much higher percentage of
TUNEL-positive cells compared to the cells with low levels of
MAD2 after treatment with same doses of cisplatin (Po0.05).
In order to test whether the MAD2-induced chemosensitivity
also occurred to another anticancer drug, taxol, a microtubule
stabilising agent, we performed colony-forming assay after
treatment with five doses of taxol on all of the cell lines. We
found that unlike observed in the cells treated with cisplatin, the
association of MAD2 and chemosensitivity to taxol was much less
significant (Figure 1C and D, right panels). These findings also
agreed with our previous observation that the expression of MAD2
had no significant effect on the chemosensitivity to taxol in NPC
cells (Wang et al, 2003).
Suppression of MEK1/2, ERK1/2 and Elk-1
phosphorylation is associated with cisplatin resistance in
cells with low level of MAD2
As discussed previously, activation of MEK/ERK pathway is critical
for cisplatin-induced apoptosis (Wang et al, 2000), and inhibition
of MEK/ERK pathway has been suggested to be responsible for
cisplatin resistance (Yeh et al, 2002). To study whether the MEK/
ERK pathway played a role in the MAD2-mediated sensitivity to
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Figure 1 Correlation of MAD2 expression and sensitivity to cisplatin and taxol. (A) MAD2 expression in 10 TGCT cell lines GH, 833K, 1411HP, NT2/
D1, 2102EP, SuSa, SuSa-CP, GCT27, GCT27R and NCCIT analysed by Western blotting. A human cervical carcinoma cell line HeLa was used as a positive
control. (B) Representative results of immunohistochemical staining of MAD2 in HeLa, GH, 833K, 1411HP, NT2/D1, 2102EP, SuSa, SuSa-CP, GCT27,
GCT27R, NCCIT cells and a negative control with primary antibody omitted. Photographs were taken under  400 magnifications. (C) Colony-forming
ability of TGCT cell lines with high (solid lines) and low (dotted lines) levels of MAD2 protein after exposure to cisplatin (left panel) and taxol (right panel).
Note that cells with high levels of MAD2 (solid lines) were more sensitive to cisplatin but not to taxol. Results represented means of three independent
experiments and error bars indicated standard deviation. (D) Colony-forming assay of acquired cisplatin-resistant cell lines and their parental lines. Results
represented means of three independent experiments and error bars indicated standard deviation. (E) Terminal deoxynucleotidyl transferase-mediated nick
end labelling staining of the 10 TGCT cell lines after treatment with three doses of cisplatin for 4 days. Note that the percentage of TUNEL-positive cells was
higher in cell lines with high level of MAD2 (NCCIT, NT2/D1, GH, 833K and SuSa) than cell lines with low levels of MAD2 (GCT27, 2102EP and 1411HP).
Results represented means of three independent experiments and error bars indicated standard deviation.
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scisplatin in TGCT cells, we first examined and compared the
expression of MEK pathway-related proteins in two cisplatin-
sensitive cell lines with relatively high levels of MAD2 (NCCIT and
GH) and two cisplatin-resistant cell lines with low levels of MAD2
(2102EP and 1411HP) after treatment with cisplatin. As shown in
Figure 2A, after treatment with cisplatin (100ngml
 1), the
sensitive NCCIT and GH cells had relatively high or sustained
levels of p-MEK 1/2, p-ERK1/2 and p-Elk-1. However, in the
relatively resistant cells, the levels of phosphorylated MAP kinases
were downregulated in a time-dependent manner. As phosphor-
ylation is an indication of activation of these proteins (Wang et al,
2000), these results suggest that decreased MAD2 expression is
associated with suppression of MAPK pathway in response to
cisplatin treatment. To investigate whether the expression of these
proteins was related to cisplatin-induced activation of the
apoptosis pathway, expression of cleaved PARP was examined by
Western blotting. As indicated in Figure 2A, the high levels of
p-MEK1/2, p-ERK1/2 and p-Elk-1 in the sensitive cells were
correlated with increased cleavage of PARP (89kDa in size), an
indicator of cells undergoing apoptosis (Ame et al, 2004),
especially at later time points. In contrast, the decreased levels of
phosphorylated MEK pathway-related proteins in resistance cells
were associated with much lower levels of PARP cleavage in
response to cisplatin treatment (100ngml
 1) (Figure 2A). These
results were also confirmed in GH and 2102EP cells treated with a
higher dose of cisplatin (500ngml
 1) (Figure 2B). These results
revealed that inhibition of MEK/ERK/Elk pathway was associated
with suppression of cisplatin-induced apoptosis in TGCT cells with
low MAD2 expression.
Inactivation of MEK/ERK pathway by an MEK1/2 inhibitor,
U0126, leads to cellular protection against cisplatin
To further confirm the importance of MEK pathway in MAD2-
mediated sensitivity to cisplatin, we next studied whether
inhibition of MEK1/2 had any effect on chemosensitivity to
Table 2 Summary of IC50 and IC90 doses of cisplatin and taxol in 10
TGCT cell lines
Cisplatin (ngml
 1) Taxol (ngml
 1)
Cell line IC507s.d. IC907s.d. IC507s.d. IC907s.d.
GH 31.0712.8 69.476.8 0.4570.02 0.8670.04
GCT27 69.2710.4 162.1718.3 0.8270.02 1.6670.11
GCT27R 242.878.5 665.6721.4 0.7170.01 1.2970.12
NCCIT 38.8075.0 99.6715.1 0.8570.08 1.6770.29
NT2/D1 23.471.34 49.875.8 0.4670.06 0.9470.21
SuSa 17.170.4 57.373.4 0.6270.01 1.0570.04
SuSa-CP 139.0713.1 345.5729.5 0.6570.02 1.2970.12
833K 36.374.7 90.3712.2 0.3870.04 0.7570.03
1411HP 189.4721.9 471.7741.9 0.7570.03 1.5070.22
2102EP 90.275.8 205.4714.4 0.6370.05 1.0870.06
p-MEK1/2
MEK1/2
p-ERK1/2
p-Elk-1
MAD2
NCCIT GH 1411HP 2102EP
Time (h)
NCCIT GH 1411HP 2102EP
PARP
Actin
Actin
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Actin
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B
0 4 8 16 24 0 4 8 16 24 0 4 8 16 24 0 4 8 16 24
116 kDa
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0 4 8 16 24 0 4 8 16 24 0 4 8 16 24 0 4 8 16 24 48 48 48 48
0 4 8 16 24 0 4 8 16 24 48 48
116 kDa
89 kDa
100 ng ml−1 cisplatin
500 ng ml
−1 cisplatin
Figure 2 Effect of cisplatin on the expression of MEK pathway-related proteins and PARP. Two TGCT cell lines expressing relatively high (NCCIT, GH)
and low levels of MAD2 (2102EP and 1411HP) were examined by Western blotting. Expression of MEK pathway-related proteins and PARP was analysed
after treatment with 100ngml
 1 (A) and 500ngml
 1 (B) of cisplatin. Note that the phosphorylation of MEK pathway-related proteins as well as cleaved
PARP were suppressed in relatively resistant cells compared to the sensitive lines.
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scisplatin in TGCT cells with high levels of MAD2. GH cells were
chosen because of their relatively high levels of MAD2 and
p-MEK1/2, p-ERK1/2 and p-Elk-1 proteins in response to cisplatin.
U0126, which had been shown to inactivate MEK-1 and MEK-2 by
reducing phosphorylation (Favata et al, 1998), was used to evaluate
whether inactivation of MEK pathway had any effect on cellular
sensitivity to cisplatin. As shown in Figure 3A, after exposure to
two concentrations of U0126 (10 and 20mM), decreased levels of p-
ERK1/2 were observed at 4h (lanes 7 and 13) compared with the
untreated control (lane 1). We also noticed that there was a slight
increase at later time points (lanes 8, 9, 14 and 15; Figure 3A)
which might be due to the gradual recovery of the cells from the
treatment or a time-dependent cisplatin-induced MEK/ERK
activation. Nevertheless, in comparison with the cells treated with
both DMSO (vehicle of U0126) and cisplatin (lanes 4, 5 and 6;
Figure 3A), U0126 treatment led to suppression of cisplatin-
induced p-ERK1/2 in GH cells (lanes 10, 11, 12, 16, 17 and 18;
Figure 3A). After exposure to both U0126 (10 and 20mM) and
cisplatin (100ngml
 1), the levels of p-ERK1/2 were decreased
notably at 4h (lanes 10 and 16; Figure 3A), 8h (lanes 11 and 17;
Figure 3A) and 24h (lanes 12 and 18; Figure 3A) when compared
to the control with the same dose of cisplatin and solvent (lanes 4–
6; Figure 3A). These results indicated that U0126 successfully
prevented the activation of ERK1/2 in the absence or presence of
cisplatin.
We then studied the effect of U0126 on chemosensitivity to
cisplatin in GH cells. We used MTT assay to determine the cell
viability of GH cells in response to cisplatin for 4, 5, 6 days in the
presence or absence of U0126 (20mM). As shown in Figure 3B–D,
after exposure to five concentrations of cisplatin (1, 2, 3, 4 and
5mgml
 1), the percentage of cell viability in U0126-treated cells
(filled columns) was higher compared with untreated cells (open
columns) in a time-dependent manner. These results suggest that
inhibition of MEK pathway is able to protect TGCT cells with high
levels of MAD2 against cisplatin-induced cell death.
Inactivation of MAD2 leads to downregulation of
MEK/ERK pathway
To further investigate the correlation between MAD2-mediated
cisplatin sensitivity and the MEK/ERK/Elk pathway, we inactivated
MAD2 in GH cells by transient transfection of a HA-tagged
dominant-negative construct of MAD2 (MAD2DC). GH cells were
studied because of their relative high levels of MAD2 and high
transfection efficiency. MAD2DC has been reported to override the
function of MAD2, therefore, it is regarded as the dominant-
negative form of MAD2 (Canman et al, 2002). As shown in
Figure 4A, HA protein was detected in cells transfected with
MAD2DC but not in the vector control cells (see the arrow). In
addition, the MAD2 level was increased when compared with the
vector control because the antibody used in this study was able to
react with both endogenous MAD2 and ectopic HA-tagged
MAD2DC proteins (Figure 4A). We also found that there was no
significant difference in the basal level of p-MEK1/2 or p-Elk-1
between the MAD2DC transfectants and the vector controls (Figure
4B and C, 0h time point), suggesting that MAD2DC alone did not
alter the phosphorylation of these kinases.
Next, we determined whether inactivation of MAD2 could lead
to any changes in the expression of MEK pathway-related proteins
and cisplatin-induced apoptosis. After exposure to two concentra-
tions of cisplatin (100 and 500ngml
 1), the levels of p-MEK and
p-ElK-1 were maintained at relatively high levels in the vector
control but the levels of these proteins were decreased in a time-
dependent manner in the MAD2DC transfectants (Figure 4B and
C). We then evaluated if the decreased p-MEK1/2 and p-Elk-1
levels could lead to any changes in cisplatin-induced apoptosis by
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scomparing the amount of cleaved PARP in the vector controls and
MAD2DC transfectants after cisplatin treatment. In parallel with
the decrease in p-MEK1/2 and p-Elk-1 protein levels, a reduction of
cleaved PARP protein was also noted in the MAD2DC transfectants
after cisplatin treatment. The relative amount of cleaved PARP was
lower in the MAD2DC transfectants compared with the vector
controls particularly at 48h post-exposure time (Figure4B and C;
100 and 500ngml
 1). These results indicated that reduced levels of
p-MEK1/2 and p-Elk-1 were associated with reduction of cisplatin-
induced apoptosis in MAD2DC transfectants.
To further establish the association between MAD2 inactivation
and cisplatin sensitivity, we performed TUNEL assay. As shown in
Figure 4D, in contrast to the vector controls (open columns), the
MAD2DC transfectants (filled columns) had significantly lower
percentage of TUNEL-positive cells when the cells were exposed to
the same doses of cisplatin (0.5 and 1.0mgml
 1 cisplatin,
Po0.001). These results indicated that inactivation of MAD2
could lead to decreased cisplatin-induced apoptosis. 3-(4,5-
Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay
also confirmed these results that MAD2DC transfectants showed
much higher cell viability (filled columns) compared with the
vector controls (open columns) in response to same concentra-
tions of cisplatin (Figure 4E–G). These results together with
Western blot analysis (Figure 4B and C) indicated that inactivation
of MAD2 led to the inhibition of MEK signalling pathway, which
was associated with resistance to cisplatin-induced cell death in
TGCT cells.
DISCUSSION
In this study, we demonstrated that downregulation of MAD2 was
associated with decreased sensitivity to cisplatin in non-isogenic
TGCT cell lines. In addition, the positive association between
MAD2 expression and cisplatin-induced MEK/ERK pathway
activation indicates that the MEK/ERK signalling pathway may
play an important role in the MAD2-mediated cisplatin sensitivity.
Although previous studies have suggested a possible role of
MAD2-mediated mitotic checkpoint in cellular response to DNA
damage (Garber and Rine, 2002; Mikhailov et al, 2002), our results
provide a possible molecular mechanism responsible for its action.
However, the fact that a reverse correlation was observed between
MAD2 expression and acquired cisplatin resistance in two pairs of
TGCT cell lines suggests that MAD2 may play a different role in
cisplatin sensitivity in the in vitro established acquired cisplatin-
resistant TGCT cell lines.
MAD2 is localised to the kinetochore, a connection between the
chromosome and the spindle, and it is required for generating the
‘wait’ signal in response to microtubule disruption. The MAD2-
dependent spindle checkpoint acts to inhibit chromosome
segregation until all chromosomes are properly attached to the
spindle, ensuring accurate partition of the genetic material in order
to preserve genome integrity (Rudner and Murray, 1996). Down-
regulation of MAD2 has been reported in several types of human
cancer including lung (Takahashi et al, 1999), breast (Li and
Benezra, 1996), nasopharyngeal (Wang et al, 2003) and ovarian
carcinomas (Wang et al, 2002). Recently, several reports have
suggested that extensive DNA damage is able to delay mitosis via
activation of the MAD2-mediated spindle assembly checkpoint
(Garber and Rine, 2002; Mikhailov et al, 2002; Nitta et al, 2004).
For example, Garger and Rine (2002) indicate that spindle
assembly checkpoint contributes to the cell cycle arrest to DNA-
damaging agents in cells lacking either the DNA damage or the
DNA replication checkpoints. In addition, it has been suggested
that disruption of the function of kinetochore by the extensive
DNA damage is able to delay mitotic exit by disruption of
kinetochore functions but not by ATM-dependent mechanisms
(Mikhailov et al, 2002). Recently, the toxicity of cisplatin has been
correlated to its binding ability to tubulin, which leads to
disruption of tubulin assembly and cell death (Tulub and Stefanov,
2001). These results support the hypothesis that mitotic check-
point may play an important part in regulating cellular response to
DNA damage. Previously, we have found that MAD2 over-
expression leads to increased sensitivity to several DNA-damaging
anticancer drugs, especially cisplatin, in NPC cells, which is
associated with activation of the apoptosis pathway (Cheung et al,
2005). The results presented in the current study also showed
that higher levels of MAD2 expression in TGCT cells were
correlated with increased sensitivity to cisplatin (Figure 1,
Table 2). In addition, inactivation of MAD2 by transfection of a
dominant-negative MAD2 construct resulted in suppression of
cisplatin-induced apoptosis and increased cell survival (Figure 4).
These results indicate that it is possible that sufficient MAD2
expression in cancer cells may be able to facilitate the activation of
the DNA damaged-induced apoptosis pathway, leading to chemo-
sensitisation.
The importance of MEK/ERK pathway in regulating apoptosis
after cisplatin treatment has been suggested. For example, ERK
activation is reported to be necessary for cisplatin-induced
apoptosis in lung cancer cells (Wang et al, 2000), cervical
carcinoma cell lines (Wang et al, 2000; Yeh et al, 2002) and
malignant TGCT cell lines (Schweyer et al, 2004a). In addition,
inactivation of MEK/ERK by its inhibitors has been shown to
prevent apoptosis in response to cisplatin leading to resistance
(Wang et al, 2000; Yeh et al, 2002), although contradictory results
have been reported (Hayakawa et al, 1999; Persons et al, 1999). In
this study, we found that activation of the MEK/ERK pathway was
associated with increased sensitivity to cisplatin-induced apoptosis
in the cells with high levels of MAD2 expression (Figure 2).
Inactivation of the MEK kinase on the other hand, led to
suppression of cisplatin-induced apoptosis in the sensitive cells
expressing high levels of MAD2 (Figure 3). In addition, inactiva-
tion of MAD2 through transfection of a dominant-negative
construct resulted in the suppression of cisplatin-induced MEK/
ERK activation, reduction of cisplatin-induced apoptosis and
cellular resistance (Figure 4). These results strongly suggest that
the MAD2-mediated cisplatin sensitivity may be regulated through
the MEK/ERK pathway. Although no direct link between MAD2
and the MEK/ERK pathway has been reported, several studies have
indicated the importance of MEK/ERK pathway in regulating
mitosis. For example, activation of the MEK/ERK pathway is
required for exit from DNA damage-induced G2 cell cycle arrest
(Abbott and Holt, 1999) and the transition from G2 into M (Lavoie
et al, 1996; Wright et al, 1999). In addition, the localisation of
active ERK to the mitotic kinetochore is also suggested to regulate
proteins involved in chromosome segregation during metaphase to
anaphase transition (Shapiro et al, 1998; Zecevic et al, 1998).
Furthermore, ERK is also described to associate with kinetochores
during early prophase, but this association is not apparent at later
stages of mitosis (Knauf et al, 2005). The fact that MAD2 functions
through its localisation to kinetochore suggests that there may be a
direct interaction between the MEK/ERK pathway and MAD2 in
regulating mitosis. Our results also agree with a study on one of the
TGCT cell lines, NCCIT, that activation of MEK/ERK pathway is
essential for the cisplatin-induced apoptosis which is associated
with increased expression of several mitosis regulators such as
cyclin B1 in response to cisplatin (Schweyer et al, 2004a). In
addition, it is reported that MAD2 mRNA levels are high in human
testis and suggests that it may play a role in spermatogenesis
(Pangilinan et al, 1997). It is possible that high levels of MAD2
expression in TGCT cells may function as a sensor for cellular
damage (i.e. DNA damage) to facilitate activation of the DNA
damaged-induced apoptosis through stimulation of the MEK/ERK
pathway. This hypothesis may also explain the fact that why TGCT
cells are hypersensitive to chemotherapeutic drugs, especially
DNA-damaging agents such as cisplatin. Our data, in general,
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Figure 4 Effect of MAD2 inactivation on MEK pathway and cellular sensitivity to cisplatin in GH cells. GH cells were transiently transfected with a HA-
tagged MAD2 dominant-negative construct (MAD2DC) and the expression of p-MEK and p-Elk, the percentage of TUNEL-positive cells and cell viability
were examined after exposure to cisplatin. (A) MAD2 and HA protein expression in MAD2DC and vector transfected GH cells 48h after transfection
(arrow indicates the size of HA protein). (B and C) Expression of p-MEK1/2 and p-Elk-1 and PARP in GH cells expressing MAD2DC and the control vector
after exposure to 100ngml
 1 (B) and 500ngml
 1 (C) cisplatin. Note that after exposure to cisplatin, the expression of p-MEK1/2 and p-Elk-1 was lower in
the MAD2DC-transfected cells especially at 48h post-exposure time compared to the vector control. (D) Terminal deoxynucleotidyl transferase-mediated
nick end labelling staining of MAD2DC transfectants (filled columns) and control vector transfectants (open columns) after exposure to three doses of
cisplatin for 4 days. Note that the percentage of TUNEL-positive cells in MAD2DC transfectants was lower than the control vector transfectants after
cisplatin treatment. Results represented means of three independent experiments and error bars indicated standard deviation. (E–G) Cell viability of
MAD2DC transfectants (filled columns) and control vector transfectants (open columns) after exposure to three concentrations of cisplatin for indicated
time points. Note that the cell viability of MAD2DC transfectants was higher than that of control vector transfectants after treatment with same doses of
cisplatin. Results represented means of three independent experiments and error bars indicated standard deviation.
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ssupport the previous view of Schweyer et al (2004a,b) that the
cisplatin-induced apoptosis depends on MEK/ERK activation in
TGCT cell lines. However, in the current study, in addition to
confirming the importance of MEK/ERK pathway in cellular
sensitivity to cisplatin, we have provided first link of this pathway
to a key component of mitotic checkpoint control, MAD2, and our
results suggest that the MAD2-mediated cisplatin sensitivity might
be regulated through the MEK/ERK pathway (Figure 5).
The proposed MAD2-induced cisplatin sensitivity model (Fig-
ure 5) also helps to explain the relatively drug-resistant phenotype
in yolk sac tumours. Histologically, GCTs with yolk sac tumour
characteristics are often insensitive to cisplatin (Dunn et al, 1997),
refractory to chemotherapy, relapse more frequently and asso-
ciated with poor survival (Toner et al, 1991). In this study, the
1411HP cells that exhibit yolk sac tumour characteristics also
had a relatively low MAD2 expression (Figure 1). In addition, there
was a much lower p-MEK/ERK level after cisplatin treatment
which was associated with decreased PARP cleavage (Figure 2A).
It is possible that the decreased MAD2 expression in yolk sac
tumour cells such as 1411HP may play a key role in suppression
of cisplatin-induced MEK/ERK activation which leads to the
suppression of apoptosis and resistance to cisplatin. Our findings
are also supported by a previous report that cisplatin resistance in
1411HP cells was associated with higher threshold for apoptosis
(Mueller et al, 2003).
In summary, we have demonstrated that high levels of MAD2
expression in TGCT cells are positively correlated with cellular
sensitivity to cisplatin. In addition, the evidence that inactivation
of MAD2 leads to suppression of MEK pathway in response to
cisplatin suggests a novel underlying mechanism responsible for
the MAD2-mediated cellular response to DNA damage. Further-
more, our results also implicate that downregulation of MAD2 may
be an indicator for identification of cisplatin resistant TGCT
patients. As cisplatin is one of the most widely use anticancer
drugs, our findings may provide a novel therapeutic target for
reversing cisplatin resistance through ectopic expression of the
MAD2 gene.
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